MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Glaukos Corp

Cerrado

SectorSalud

100.08 3.53

Resumen

Variación precio

24h

Actual

Mínimo

93.88

Máximo

100.43

Métricas clave

By Trading Economics

Ingresos

-12M

-34M

Ventas

8.8M

105M

BPA

-0.4

Margen de beneficio

-31.83

Empleados

995

EBITDA

-12M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+64.43% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1.2B

5.8B

Apertura anterior

96.55

Cierre anterior

100.08

Noticias sobre sentimiento de mercado

By Acuity

33%

67%

106 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Glaukos Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

2 abr 2025, 23:55 UTC

Acciones populares

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 abr 2025, 22:50 UTC

Principales Movimientos del Mercado

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 abr 2025, 21:08 UTC

Ganancias

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 abr 2025, 21:00 UTC

Ganancias

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 abr 2025, 23:56 UTC

Charlas de Mercado

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 abr 2025, 23:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 abr 2025, 23:44 UTC

Charlas de Mercado

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 abr 2025, 23:44 UTC

Principales Noticias

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 abr 2025, 23:32 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 23:32 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 abr 2025, 23:32 UTC

Charlas de Mercado

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 abr 2025, 23:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 abr 2025, 23:12 UTC

Charlas de Mercado

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 abr 2025, 23:10 UTC

Charlas de Mercado

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 abr 2025, 23:09 UTC

Charlas de Mercado

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 abr 2025, 23:09 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 22:57 UTC

Charlas de Mercado

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 abr 2025, 22:56 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 22:56 UTC

Charlas de Mercado

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 abr 2025, 22:43 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 abr 2025, 22:12 UTC

Charlas de Mercado

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 abr 2025, 21:48 UTC

Principales Noticias

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 abr 2025, 21:41 UTC

Charlas de Mercado

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 abr 2025, 21:17 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 21:17 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 abr 2025, 21:17 UTC

Charlas de Mercado

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 abr 2025, 21:04 UTC

Principales Noticias

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 abr 2025, 21:03 UTC

Charlas de Mercado

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 abr 2025, 20:53 UTC

Ganancias

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 abr 2025, 20:52 UTC

Ganancias

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparación entre iguales

Cambio de precio

Glaukos Corp Esperado

Precio Objetivo

By TipRanks

64.43% repunte

Estimación a 12 meses

Media 164.5 USD  64.43%

Máximo 200 USD

Mínimo 110 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Glaukos Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

0

Mantener

1

Vender

Puntuación técnica

By Trading Central

98.42 / 102.44Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

106 / 386 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.